Equity in Access Research Grants
The Equity in Access Research Program by the Leukemia & Lymphoma Society seeks to generate evidence guiding policy and practice reforms that reduce social, economic, and environmental barriers to blood cancer care. Through funding studies that implement and evaluate interventions to improve therapeutic cancer clinical trial accrual—especially among underrepresented populations—LLS aims to promote more equitable access for patients and survivors.
Eligibility Criteria
-
Principal investigators at academic, clinical, or non-profit institutions
-
Studies must focus on interventions addressing systemic, institutional, or clinician-related barriers to trial participation
-
Emphasis on underrepresented groups in therapeutic cancer clinical trials
Funding Details
-
Seed funding to support implementation and quantitative evaluation of accrual interventions
-
Exact budget limit not specified in LOI stage; details provided in full proposal guidelines
-
Projects start July 1, 2026
Deadlines & Timeline
-
Webinar for Applicants: June 18, 2025 (12 PM ET)
-
Letters of Intent Due: September 11, 2025 (3 PM ET)
-
Full Proposal Invitations: October 31, 2025
-
Full Proposals Due: January 29, 2026 (3 PM ET)
-
Award Notifications: April/May 2026
Where to Apply
-
For questions, contact [email protected]
- Application guide.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023